Pathophysiology and Management of Type 2 Diabetes

Type 2 diabetes arises from a complex interplay between genetic predisposition and environmental factors, leading to chronic hyperglycaemia and multiorgan dysfunction. Central to disease onset is insulin resistance in peripheral tissues—particularly skeletal muscle, adipose tissue and liver—combined with progressive pancreatic β-cell dysfunction. Early compensatory hyperinsulinaemia gives way to β-cell failure, driven by glucotoxicity, lipotoxicity and islet inflammation. Dysregulation of incretin hormones, altered gut microbiota and low-grade systemic inflammation further exacerbate metabolic disturbance. Over time, sustained hyperglycaemia and vascular dysfunction give rise to microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease (cardiovascular and cerebrovascular events, peripheral arterial disease). Management hinges on a staged approach: lifestyle modification (dietary optimisation, structured exercise), self-monitoring of blood glucose and individualised pharmacotherapy. First-line treatment typically comprises metformin with subsequent addition of agents targeting insulin secretion or action, such as sulfonylureas, thiazolidinediones, GLP-1 receptor agonists and SGLT2 inhibitors. Emergent strategies include digital health integration, closed-loop insulin delivery and novel peptide or RNA-based therapeutics aimed at preserving β-cell mass or attenuating hepatic gluconeogenesis. A holistic approach addressing comorbidities—hypertension, dyslipidaemia and obesity—remains essential to reduce morbidity and mortality on a global scale.

Research from Nature Portfolio

Recent single-cell transcriptomic studies have dissected human islet composition under metabolic stress, revealing subpopulations of β-cells with distinct adaptive and maladaptive signatures that may predict resilience or progression to failure. Parallel work on dual and triagonist peptide therapies has demonstrated in preclinical models superior glycaemic control and weight reduction compared with monoagonist treatment, suggesting a path to more effective polypharmacology. In addition, RNA interference strategies targeting key hepatic enzymes have shown proof-of-concept for reducing gluconeogenic flux in rodent and primate studies, opening avenues for precision modulation of endogenous glucose production.

Pathophysiology and Management of Type 2 Diabetes publication trend

The graph below shows the total number of articles in pathophysiology and management of type 2 diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Insulin resistance: Reduced responsiveness of muscle and adipose tissue to insulin, impairing glucose uptake.

Beta-cell dysfunction: Inadequate insulin secretion due to progressive impairment of pancreatic β-cells.

Incretins: Gut-derived hormones (GLP-1, GIP) that amplify insulin release in response to nutrient intake.

SGLT2 inhibitor: Agent that lowers blood glucose by inhibiting renal glucose reabsorption.

HbA1c: Glycated haemoglobin reflecting average glucose exposure over the preceding two to three months.

References

1. Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case–control study. Diabetologia (2024).
2. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (2019).